PerkinElmer,
Inc. (NYSE: PKI), a global leader focused on improving the health
and safety of people and the environment, today reported financial
results for the first quarter ended April 5, 2009. The Company reported
GAAP earnings per share from continuing operations of $0.13, down from
the same period a year ago due primarily to a restructuring charge and a
higher tax rate. On a non-GAAP basis, which includes the adjustments
noted in the attached reconciliation, the Company announced adjusted
earnings per share of $0.26, which exceeds the Company’s prior guidance
of $0.21-$0.23.
Organic revenue growth, which includes the adjustments noted in the
attached reconciliation, was flat as compared to the first quarter of
2008. Revenue from continuing operations in the Human Health and
Environmental Health segments decreased by 2% and 9% respectively as
compared to the same period a year ago. Organic revenue in the Human
Health segment was up by 3% and organic revenue in the Environmental
Health segment was down by 3% as compared to the same period a year ago.
"We are pleased to have started 2009 with better than expected results
in both revenue and adjusted earnings per share,” said Robert Friel,
chairman and chief executive officer of PerkinElmer. "Our increased
focus on human and environmental health applications and our broad array
of service offerings is enabling us to do relatively well despite the
challenging economic environment.”
GAAP operating profit from continuing operations for the first quarter
of 2009 was $25.7 million, compared to $33.4 million for the same period
a year ago. On a non-GAAP basis, which includes the adjustments noted in
the attached reconciliation, adjusted operating profit for the first
quarter of 2009 was $48.4 million as compared to $48.4 million in the
first quarter of 2008, representing a 70 basis point expansion in
adjusted operating profit margins.
GAAP earnings per share from continuing operations for the first quarter
of 2009 was $0.13 as compared to $0.18 for the same period in 2008. On a
non-GAAP basis, which includes the adjustments noted in the attached
reconciliation, adjusted earnings per share for the first quarter of
2009 was $0.26, which was flat as compared to $0.26 in the first quarter
of 2008.
For the first quarter of 2009, operating cash flow from continuing
operations was $18.8 million as compared to $24.9 million from the same
period one year ago. In the first quarter of 2009, the Company reduced
the amount drawn under an accounts receivable securitization facility by
$10.0 million, resulting in an unfavorable impact to operating cash
flow. On a non-GAAP basis, which excludes the reduction in the amount
outstanding under this facility, the adjusted operating cash flow was
$28.8 million in the first quarter of 2009 representing a 16% increase
from the same period a year ago.
Financial Overview by Reporting Segment
Human Health reported revenue of $177.3 million for the first
quarter of 2009. The segment’s GAAP operating profit for the first
quarter of 2009 was $12.7 million, compared to $11.8 million for the
same period a year ago. On a non-GAAP basis, which includes the
adjustments noted in the attached reconciliation, the segment’s adjusted
operating profit for the first quarter 2009 was $27.6 million, as
compared to $23.1 million in the first quarter of 2008. As a percentage
of revenue, the segment’s adjusted operating profit for the first
quarter of 2009 was up 280 basis points as compared to the first quarter
of 2008.
Environmental Health reported revenue of $254.3 million for the
first quarter of 2009. The segment’s GAAP operating profit for the first
quarter of 2009 was $20.6 million, compared to $31.6 million for the
same period a year ago. On a non-GAAP basis, which includes the
adjustments noted in the attached reconciliation, the segment’s adjusted
operating profit for the first quarter of 2009 was $28.4 million, as
compared to $35.4 million in the first quarter of 2008. As a percentage
of revenue, the segment’s adjusted operating profit for the first
quarter of 2009 was down 150 basis points as compared to the first
quarter of 2008.
Financial Guidance
"While several of our end markets appear to be stabilizing, we believe
there continues to be risk in the global economy. Therefore, despite our
strong first quarter financial performance, we feel it prudent, at this
time, to keep our full year revenue and adjusted earnings guidance
unchanged,” said Friel.
In January of 2009, the Company forecasted for the full year 2009
organic revenue growth relative to 2008 to be flat to down mid-single
digits. The Company forecasted 2009 earnings per share relative to 2008
to be down mid-single digits to mid-teens on both a GAAP and non-GAAP
basis, which includes the impact of stock option expense in both periods.
Conference Call Information
The Company will discuss its first quarter results and its outlook for
business trends in a conference call on April 30, 2009 at 5:00 p.m.
Eastern Time (ET). To access the call, please dial (617) 213-8052 prior
to the scheduled conference call time and provide the access code
77376121. A replay of this conference call will be available
approximately two hours after the call. The replay phone number is (617)
801-6888 and the code number is 70103308.
A live audio webcast of the call will be available on the Investor
section of the Company’s Web site, www.perkinelmer.com.
Please go to the site at least 15 minutes prior to the call in order to
register, download, and install any necessary software. An archived
version of the webcast will be posted on the Company’s Web site for a
two week period beginning approximately two hours after the call.
Use of Non-GAAP Financial Measures
In addition to financial measures prepared in accordance with generally
accepted accounting principles (GAAP), this earnings announcement also
contains non-GAAP financial measures. The reasons that we use these
measures, a reconciliation of these measures to the most directly
comparable GAAP measures, and other information relating to these
measures are included below following our GAAP financial statements.
Factors Affecting Future Performance
This press release contains "forward-looking" statements within the
meaning of the Private Securities Litigation Reform Act of 1995,
including, but not limited to, statements relating to estimates and
projections of future earnings per share, cash flow and revenue growth
and other financial results, developments relating to our customers and
end-markets, and plans concerning business development opportunities.
Words such as "believes," "intends," "anticipates," "plans," "expects,"
"projects," "forecasts," "will" and similar expressions, and references
to guidance, are intended to identify forward-looking statements. Such
statements are based on management's current assumptions and
expectations and no assurances can be given that our assumptions or
expectations will prove to be correct. A number of important risk
factors could cause actual results to differ materially from the results
described, implied or projected in any forward-looking statements. These
factors include, without limitation: (1) markets into which we sell our
products decline or do not grow as anticipated; (2) fluctuations in the
global economic and political environments; (3) our failure to introduce
new products in a timely manner; (4) our ability to execute acquisitions
and license technologies, or to successfully integrate acquired
businesses and licensed technologies into our existing business or to
make them profitable; (5) our failure to adequately protect our
intellectual property; (6) the loss of any of our licenses or licensed
rights; (7) our ability to compete effectively; (8) fluctuation in our
quarterly operating results and our ability to adjust our operations to
address unexpected changes; (9) significant disruption in third-party
package delivery and import/export services or significant increases in
prices for those services; (10) disruptions in the supply of raw
materials and supplies; (11) the manufacture and sale of products may
expose us to product liability claims; (12) our failure to maintain
compliance with applicable government regulations; (13) regulatory
changes; (14) our failure to comply with health care industry
regulations; (15) economic, political and other risks associated with
foreign operations; (16) our ability to retain key personnel; (17)
significant disruption in our information technology systems; (18)
restrictions in our credit agreements; (19) our ability to realize the
full value of our intangible assets; (20) significant fluctuations in
our stock price; (21) reduction or elimination of dividends on our
common stock; and (22) other factors which we describe under the caption
"Risk Factors" in our most recent annual report on Form 10-K and in our
other filings with the Securities and Exchange Commission. We disclaim
any intention or obligation to update any forward-looking statements as
a result of developments occurring after the date of this press release.
About PerkinElmer
PerkinElmer, Inc. is a global leader focused on improving the health and
safety of people and the environment. The Company reported revenue of
approximately $2 billion in 2008, has around 8,500 employees serving
customers in more than 150 countries, and is a component of the S&P 500
Index. Additional information is available through www.perkinelmer.com
or 1-877-PKI-NYSE.
|
PerkinElmer, Inc. and Subsidiaries
|
|
|
CONSOLIDATED INCOME STATEMENTS
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
(In thousands, except per share data)
|
|
April 5, 2009
|
|
March 30, 2008
|
|
|
|
|
|
|
|
|
|
Sales
|
|
$
|
431,574
|
|
|
$
|
458,720
|
|
|
|
|
|
|
|
|
|
Cost of sales
|
|
|
243,619
|
|
|
|
266,606
|
|
|
Research and development expenses
|
|
|
25,973
|
|
|
|
27,847
|
|
|
Selling, general and administrative expenses
|
|
|
128,414
|
|
|
|
130,834
|
|
|
Restructuring charges, net
|
|
|
7,823
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
Operating income from continuing operations
|
|
|
25,745
|
|
|
|
33,433
|
|
|
|
|
|
|
|
|
|
Interest income
|
|
|
(477
|
)
|
|
|
(1,358
|
)
|
|
Interest expense
|
|
|
4,588
|
|
|
|
6,318
|
|
|
Gains on dispositions of investments, net
|
|
|
-
|
|
|
|
(889
|
)
|
|
Other expense, net
|
|
|
726
|
|
|
|
1,239
|
|
|
|
|
|
|
|
|
|
Income from continuing operations before income taxes
|
|
|
20,908
|
|
|
|
28,123
|
|
|
|
|
|
|
|
|
|
Provision for income taxes
|
|
|
5,847
|
|
|
|
7,384
|
|
|
|
|
|
|
|
|
|
Net income from continuing operations
|
|
|
15,061
|
|
|
|
20,739
|
|
|
|
|
|
|
|
|
|
Loss from discontinued operations, net of income taxes
|
|
|
(2,913
|
)
|
|
|
(232
|
)
|
|
Loss on disposition of discontinued operations, net of income taxes
|
|
|
(1,589
|
)
|
|
|
(369
|
)
|
|
|
|
|
|
|
|
|
Net income
|
|
$
|
10,559
|
|
|
$
|
20,138
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted earnings (loss) per share:
|
|
|
|
|
|
|
Continuing operations
|
|
$
|
0.13
|
|
|
$
|
0.18
|
|
|
|
|
|
|
|
|
|
Loss from discontinued operations, net of income taxes
|
|
|
(0.02
|
)
|
|
|
(0.00
|
)
|
|
Loss on disposition of discontinued operations, net of income taxes
|
|
|
(0.01
|
)
|
|
|
(0.00
|
)
|
|
|
|
|
|
|
|
|
Net income
|
|
$
|
0.09
|
|
|
$
|
0.17
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average diluted shares of common stock outstanding
|
|
|
116,552
|
|
|
|
118,459
|
|
|
|
|
|
|
|
|
|
ABOVE PREPARED IN ACCORDANCE WITH GAAP
|
|
|
|
|
|
|
|
|
Additional Supplemental Information:
|
|
|
|
|
|
|
(per share, continuing operations)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GAAP diluted EPS from continuing operations
|
|
$
|
0.13
|
|
|
$
|
0.18
|
|
|
Amortization of intangible assets, net of income taxes
|
|
|
0.07
|
|
|
|
0.07
|
|
|
Purchase accounting adjustments, net of income taxes
|
|
|
0.01
|
|
|
|
0.01
|
|
|
Restructuring charges, net of income taxes
|
|
|
0.05
|
|
|
|
-
|
|
|
Adjusted EPS
|
|
$
|
0.26
|
|
|
$
|
0.26
|
|
|
|
|
|
|
|
|
|
|
|
|
PerkinElmer, Inc. and Subsidiaries
|
|
SALES AND OPERATING PROFIT (LOSS)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
(In thousands)
|
|
|
|
|
April 5, 2009
|
|
|
March 30, 2008
|
|
|
|
|
|
|
|
|
|
|
|
Human Health
|
|
Sales
|
|
$
|
177,264
|
|
$
|
180,089
|
|
|
|
OP$ reported
|
|
|
12,687
|
|
|
11,833
|
|
|
|
OP% reported
|
|
|
7.2%
|
|
|
6.6%
|
|
|
|
Amortization of intangible assets
|
|
|
9,779
|
|
|
9,865
|
|
|
|
Purchase accounting adjustments
|
|
|
365
|
|
|
1,353
|
|
|
|
Restructuring charges
|
|
|
4,774
|
|
|
-
|
|
|
|
OP$ adjusted
|
|
|
27,605
|
|
|
23,051
|
|
|
|
OP% adjusted
|
|
|
15.6%
|
|
|
12.8%
|
|
|
|
|
|
|
|
|
|
|
|
Environmental Health
|
|
Sales
|
|
|
254,310
|
|
|
278,631
|
|
|
|
OP$ reported
|
|
|
20,631
|
|
|
31,636
|
|
|
|
OP% reported
|
|
|
8.1%
|
|
|
11.4%
|
|
|
|
Amortization of intangible assets
|
|
|
3,626
|
|
|
3,720
|
|
|
|
Purchase accounting adjustments
|
|
|
1,052
|
|
|
-
|
|
|
|
Restructuring charges
|
|
|
3,049
|
|
|
-
|
|
|
|
OP$ adjusted
|
|
|
28,358
|
|
|
35,356
|
|
|
|
OP% adjusted
|
|
|
11.2%
|
|
|
12.7%
|
|
|
|
|
|
|
|
|
|
|
|
Corporate
|
|
OP$ reported
|
|
|
(7,573)
|
|
|
(10,036)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Continuing Operations
|
|
Sales
|
|
$
|
431,574
|
|
$
|
458,720
|
|
|
|
OP$ reported
|
|
|
25,745
|
|
|
33,433
|
|
|
|
OP% reported
|
|
|
6.0%
|
|
|
7.3%
|
|
|
|
Amortization of intangible assets
|
|
|
13,405
|
|
|
13,585
|
|
|
|
Purchase accounting adjustments
|
|
|
1,417
|
|
|
1,353
|
|
|
|
Restructuring charges
|
|
|
7,823
|
|
|
-
|
|
|
|
OP$ adjusted
|
|
$
|
48,390
|
|
$
|
48,371
|
|
|
|
OP% adjusted
|
|
|
11.2%
|
|
|
10.5%
|
|
|
|
|
|
|
|
|
|
|
|
SALES AND REPORTED OPERATING PROFIT PREPARED IN ACCORDANCE WITH GAAP
|
|
PerkinElmer, Inc. and Subsidiaries
|
|
CONSOLIDATED BALANCE SHEETS
|
|
|
|
|
|
|
|
(In thousands)
|
|
April 5, 2009
|
|
December 28, 2008
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current assets:
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
162,049
|
|
|
$
|
179,110
|
|
|
Accounts receivable, net
|
|
|
292,105
|
|
|
|
327,636
|
|
|
Inventories, net
|
|
|
204,172
|
|
|
|
197,967
|
|
|
Other current assets
|
|
|
107,817
|
|
|
|
111,087
|
|
|
Current assets of discontinued operations
|
|
|
14,382
|
|
|
|
14,947
|
|
|
Total current assets
|
|
|
780,525
|
|
|
|
830,747
|
|
|
|
|
|
|
|
|
Property, plant and equipment, net:
|
|
|
|
|
|
At cost
|
|
|
560,549
|
|
|
|
570,257
|
|
|
Accumulated depreciation
|
|
|
(362,205
|
)
|
|
|
(365,843
|
)
|
|
Property, plant and equipment, net
|
|
|
198,344
|
|
|
|
204,414
|
|
|
Marketable securities and investments
|
|
|
3,078
|
|
|
|
3,459
|
|
|
Intangible assets, net
|
|
|
449,493
|
|
|
|
452,473
|
|
|
Goodwill
|
|
|
1,385,268
|
|
|
|
1,396,292
|
|
|
Other assets, net
|
|
|
36,286
|
|
|
|
38,760
|
|
|
Long-term assets of discontinued operations
|
|
|
5,499
|
|
|
|
5,622
|
|
|
Total assets
|
|
$
|
2,858,493
|
|
|
$
|
2,931,767
|
|
|
|
|
|
|
|
|
Current liabilities:
|
|
|
|
|
|
Short-term debt
|
|
$
|
40
|
|
|
$
|
40
|
|
|
Accounts payable
|
|
|
143,347
|
|
|
|
169,447
|
|
|
Accrued restructuring and integration costs
|
|
|
10,845
|
|
|
|
5,904
|
|
|
Accrued expenses
|
|
|
297,954
|
|
|
|
323,815
|
|
|
Current liabilities of discontinued operations
|
|
|
16,659
|
|
|
|
17,036
|
|
|
Total current liabilities
|
|
|
468,845
|
|
|
|
516,242
|
|
|
|
|
|
|
|
|
Long-term debt
|
|
|
544,030
|
|
|
|
509,040
|
|
|
Long-term liabilities
|
|
|
330,317
|
|
|
|
335,354
|
|
|
Long-term liabilities of discontinued operations
|
|
|
2,900
|
|
|
|
3,188
|
|
|
Total liabilities
|
|
|
1,346,092
|
|
|
|
1,363,824
|
|
|
|
|
|
|
|
|
Commitments and contingencies
|
|
|
|
|
|
|
|
|
|
|
|
Total stockholders' equity
|
|
|
1,512,401
|
|
|
|
1,567,943
|
|
|
Total liabilities and stockholders' equity
|
|
$
|
2,858,493
|
|
|
$
|
2,931,767
|
|
|
|
|
|
|
|
|
PREPARED IN ACCORDANCE WITH GAAP
|
|
PerkinElmer, Inc. and Subsidiaries
|
|
CONSOLIDATED STATEMENTS OF CASH FLOWS
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
|
April 5, 2009
|
|
March 30, 2008
|
|
(In thousands)
|
|
|
|
|
|
|
|
|
|
|
|
Operating activities:
|
|
|
|
|
|
Net income
|
|
$ 10,559
|
|
$ 20,138
|
|
Add: loss from discontinued operations, net of income taxes
|
|
2,913
|
|
232
|
|
Add: loss on disposition of discontinued operations, net of income
taxes
|
|
1,589
|
|
369
|
|
Net income from continuing operations
|
|
15,061
|
|
20,739
|
|
Adjustments to reconcile net income from continuing operations to
net cash provided by continuing operations:
|
|
|
|
|
|
Stock-based compensation
|
|
3,806
|
|
5,209
|
|
Restructuring charges
|
|
7,823
|
|
-
|
|
Amortization of deferred debt issuance costs
|
|
635
|
|
381
|
|
Depreciation and amortization
|
|
21,601
|
|
21,597
|
|
Amortization of acquired inventory revaluation
|
|
215
|
|
-
|
|
Gains on dispositions, net
|
|
-
|
|
(889)
|
|
Changes in operating assets and liabilities:
|
|
|
|
|
|
Accounts receivable, net
|
|
20,406
|
|
6,953
|
|
Inventories, net
|
|
(12,527)
|
|
(11,427)
|
|
Accounts payable
|
|
(20,784)
|
|
3,957
|
|
Accrued expenses and other
|
|
(17,409)
|
|
(21,658)
|
|
Net cash provided by operating activities of continuing operations
|
|
18,827
|
|
24,862
|
|
Net cash used in operating activities of discontinued operations
|
|
(3,882)
|
|
(9,257)
|
|
Net cash provided by operating activities
|
|
14,945
|
|
15,605
|
|
|
|
|
|
|
|
Investing activities:
|
|
|
|
|
|
Capital expenditures
|
|
(5,632)
|
|
(6,703)
|
|
Changes in restricted cash balances
|
|
1,412
|
|
-
|
|
Payments for business development activity
|
|
-
|
|
(144)
|
|
Proceeds from disposition of businesses and investments, net
|
|
-
|
|
889
|
|
Payments for acquisitions and investments, net of cash and cash
equivalents acquired
|
|
(28,311)
|
|
(76,232)
|
|
Net cash used in investing activities of continuing operations
|
|
(32,531)
|
|
(82,190)
|
|
Net cash used in investing activities of discontinued operations
|
|
-
|
|
(621)
|
|
Net cash used in investing activities
|
|
(32,531)
|
|
(82,811)
|
|
|
|
|
|
|
|
Financing Activities:
|
|
|
|
|
|
Payments on debt
|
|
(71,564)
|
|
(305,000)
|
|
Proceeds from borrowings
|
|
105,000
|
|
355,000
|
|
Payments for debt issuance costs
|
|
(7)
|
|
(585)
|
|
Decrease in other credit facilities
|
|
(10)
|
|
(16)
|
|
Tax (expense) benefit from exercise of common stock options
|
|
(76)
|
|
4
|
|
Proceeds from issuance of common stock under stock plans
|
|
304
|
|
646
|
|
Purchases of common stock
|
|
(14,577)
|
|
(408)
|
|
Dividends paid
|
|
(8,205)
|
|
(8,236)
|
|
Net cash provided by financing activities
|
|
10,865
|
|
41,405
|
|
|
|
|
|
|
|
Effect of exchange rate changes on cash and cash equivalents
|
|
(10,340)
|
|
7,715
|
|
|
|
|
|
|
|
Net decrease in cash and cash equivalents
|
|
(17,061)
|
|
(18,086)
|
|
Cash and cash equivalents at beginning of period
|
|
179,110
|
|
203,348
|
|
Cash and cash equivalents at end of period
|
|
$ 162,049
|
|
$ 185,262
|
|
|
|
|
|
|
|
PREPARED IN ACCORDANCE WITH GAAP
|
|
PerkinElmer, Inc. and Subsidiaries
|
|
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PKI
|
|
|
|
Q109
|
|
|
|
Q108
|
|
|
|
Adjusted gross margin:
|
|
|
|
|
|
|
|
|
|
GAAP gross margin
|
|
$
|
188.0
|
|
|
43.6
|
%
|
|
$
|
192.1
|
|
|
41.9
|
%
|
|
Amortization of intangible assets
|
|
|
8.8
|
|
|
2.0
|
%
|
|
|
9.2
|
|
|
2.0
|
%
|
|
Purchase accounting adjustments
|
|
|
0.4
|
|
|
0.1
|
%
|
|
|
1.4
|
|
|
0.3
|
%
|
|
Adjusted gross margin
|
|
$
|
197.1
|
|
|
45.7
|
%
|
|
$
|
202.6
|
|
|
44.2
|
%
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted SG&A:
|
|
|
|
|
|
|
|
|
|
GAAP SG&A
|
|
$
|
128.4
|
|
|
29.8
|
%
|
|
$
|
130.8
|
|
|
28.5
|
%
|
|
Amortization of intangible assets
|
|
|
(4.2
|
)
|
|
-1.0
|
%
|
|
|
(3.9
|
)
|
|
-0.8
|
%
|
|
Purchase accounting adjustments
|
|
|
(1.0
|
)
|
|
-0.2
|
%
|
|
|
-
|
|
|
0.0
|
%
|
|
Adjusted SG&A
|
|
$
|
123.2
|
|
|
28.5
|
%
|
|
$
|
127.0
|
|
|
27.7
|
%
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted R&D:
|
|
|
|
|
|
|
|
|
|
GAAP R&D
|
|
$
|
26.0
|
|
|
6.0
|
%
|
|
$
|
27.8
|
|
|
6.1
|
%
|
|
Amortization of intangible assets
|
|
|
(0.5
|
)
|
|
-0.1
|
%
|
|
|
(0.5
|
)
|
|
-0.1
|
%
|
|
Adjusted R&D
|
|
$
|
25.5
|
|
|
5.9
|
%
|
|
$
|
27.3
|
|
|
6.0
|
%
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted operating profit:
|
|
|
|
|
|
|
|
|
|
GAAP operating profit
|
|
$
|
25.7
|
|
|
6.0
|
%
|
|
$
|
33.4
|
|
|
7.3
|
%
|
|
Amortization of intangible assets
|
|
|
13.4
|
|
|
3.1
|
%
|
|
|
13.6
|
|
|
3.0
|
%
|
|
Purchase accounting adjustments
|
|
|
1.4
|
|
|
0.3
|
%
|
|
|
1.4
|
|
|
0.3
|
%
|
|
Restructuring charges
|
|
|
7.8
|
|
|
1.8
|
%
|
|
|
-
|
|
|
0.0
|
%
|
|
Adjusted operating profit
|
|
$
|
48.4
|
|
|
11.2
|
%
|
|
$
|
48.4
|
|
|
10.5
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PKI
|
|
|
|
Q109
|
|
|
|
Q108
|
|
|
|
Adjusted operating cash flow:
|
|
|
|
|
|
|
|
|
|
GAAP cash flow from continuing operations
|
|
$
|
18.8
|
|
|
|
|
$
|
24.9
|
|
|
|
|
Reduction of accounts receivable securitization
|
|
|
10.0
|
|
|
|
|
|
-
|
|
|
|
|
Adjusted operating cash flow
|
|
$
|
28.8
|
|
|
|
|
$
|
24.9
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PKI
|
|
|
|
Q109
|
|
|
|
Q108
|
|
|
|
Adjusted EPS:
|
|
|
|
|
|
|
|
|
|
GAAP EPS
|
|
$
|
0.09
|
|
|
|
|
$
|
0.17
|
|
|
|
|
Discontinued operations
|
|
|
(0.04
|
)
|
|
|
|
|
(0.01
|
)
|
|
|
|
GAAP EPS from continuing operations
|
|
|
0.13
|
|
|
|
|
|
0.18
|
|
|
|
|
Amortization of intangible assets, net of income taxes
|
|
|
0.07
|
|
|
|
|
|
0.07
|
|
|
|
|
Purchase accounting adjustments, net of income taxes
|
|
|
0.01
|
|
|
|
|
|
0.01
|
|
|
|
|
Restructuring charges, net of income taxes
|
|
|
0.05
|
|
|
|
|
|
-
|
|
|
|
|
Adjusted EPS
|
|
$
|
0.26
|
|
|
|
|
$
|
0.26
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Human Health
|
|
|
|
Q109
|
|
|
|
Q108
|
|
|
|
Adjusted operating profit:
|
|
|
|
|
|
|
|
|
|
GAAP operating profit
|
|
$
|
12.7
|
|
|
7.2
|
%
|
|
$
|
11.8
|
|
|
6.6
|
%
|
|
Amortization of intangible assets
|
|
|
9.8
|
|
|
5.5
|
%
|
|
|
9.9
|
|
|
5.5
|
%
|
|
Purchase accounting adjustments
|
|
|
0.4
|
|
|
0.2
|
%
|
|
|
1.4
|
|
|
0.8
|
%
|
|
Restructuring charges
|
|
|
4.8
|
|
|
2.7
|
%
|
|
|
-
|
|
|
0.0
|
%
|
|
Adjusted operating profit
|
|
$
|
27.6
|
|
|
15.6
|
%
|
|
$
|
23.1
|
|
|
12.8
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Environmental Health
|
|
|
|
Q109
|
|
|
|
Q108
|
|
|
|
Adjusted operating profit:
|
|
|
|
|
|
|
|
|
|
GAAP operating profit
|
|
$
|
20.6
|
|
|
8.1
|
%
|
|
$
|
31.6
|
|
|
11.4
|
%
|
|
Amortization of intangible assets
|
|
|
3.6
|
|
|
1.4
|
%
|
|
|
3.7
|
|
|
1.3
|
%
|
|
Purchase accounting adjustments
|
|
|
1.1
|
|
|
0.4
|
%
|
|
|
-
|
|
|
0.0
|
%
|
|
Restructuring charges
|
|
|
3.0
|
|
|
1.2
|
%
|
|
|
-
|
|
|
0.0
|
%
|
|
Adjusted operating profit
|
|
$
|
28.4
|
|
|
11.2
|
%
|
|
$
|
35.4
|
|
|
12.7
|
%
|
|
PerkinElmer, Inc. and Subsidiaries
|
|
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES
|
|
|
|
|
|
|
|
Human Health
|
|
|
|
Q109
|
|
Organic revenue growth:
|
|
|
|
Reported revenue growth
|
|
-2%
|
|
Less effect of foreign exchange rates
|
|
-7%
|
|
Less effect of acquisitions
|
|
1%
|
|
Organic revenue growth
|
|
3%
|
|
|
|
|
|
|
|
|
|
|
|
Environmental Health
|
|
|
|
Q109
|
|
Organic revenue growth:
|
|
|
|
Reported revenue growth
|
|
-9%
|
|
Less effect of foreign exchange rates
|
|
-7%
|
|
Less effect of acquisitions
|
|
2%
|
|
Organic revenue growth
|
|
-3%
|
|
|
|
|
|
|
|
|
|
|
|
PKI
|
|
|
|
Q109
|
|
Organic revenue growth:
|
|
|
|
Reported revenue growth
|
|
-6%
|
|
Less effect of foreign exchange rates
|
|
-7%
|
|
Less effect of acquisitions
|
|
1%
|
|
Organic revenue growth
|
|
0%
|
Organic Revenue and Organic Revenue
Growth
We use the term "organic revenue” to refer to GAAP revenue, excluding
the effect of foreign currency translation and acquisitions. We use the
related term "organic revenue growth” to refer to the measure of
comparing current period organic revenue with the corresponding period
of the prior year. We believe that these non-GAAP measures, when taken
together with our GAAP financial measures, allow us and our investors to
better measure the performance of our investments in technology, to
evaluate the long-term performance trends and to assess our ability to
invest in the business. Organic revenue growth also provides for easier
comparisons of our performance with prior and future periods and
relative comparisons to our peers. We exclude the effect of foreign
currency translation from these measures because foreign currency
translation is subject to volatility and can obscure underlying trends.
We exclude the effect of acquisitions because acquisition activity can
vary dramatically between reporting periods and between us and our
peers, which we believe makes comparisons of long-term performance
trends difficult for management and investors, and could result in
overstating or understating to our investors the performance of our
operations.
Adjusted Gross Margin and Adjusted
Gross Margin Percentage
We use the term "adjusted gross margin” to refer to GAAP gross margin,
excluding amortization of intangible assets and inventory fair value
adjustments related to business acquisitions, and including estimated
revenue from contracts acquired in the acquisition of ViaCell, Inc., or
ViaCell, that will not be fully recognized due to business combination
accounting rules. We use the related term "adjusted gross margin
percentage” to refer to adjusted gross margin as a percentage of GAAP
revenue. We believe that these non-GAAP measures, when taken together
with our GAAP financial measures, allow us and our investors to better
measure the performance of our investments in technology, to evaluate
the long-term profitability trends and to assess our ability to invest
in the business. We exclude amortization of intangible assets from these
measures because intangibles amortization charges do not represent what
our management and what we believe our investors consider to be costs of
producing our products and could distort the additional value generated
over the cost of producing those products. Inventory fair value
adjustments related to business acquisitions also do not represent what
our management and what we believe our investors consider to be costs
used in producing our products. We include estimated revenue from
contracts acquired in the ViaCell acquisition that will not be fully
recognized because our GAAP revenue for the periods subsequent to our
acquisition do not reflect the full amount of storage revenue on these
contracts that would have otherwise been recorded by ViaCell. The
non-GAAP adjustment is intended to reflect the full amount of such
revenue. Our management and we believe our investors will use this
adjustment as a measure of the ongoing performance of the ViaCell
business because customers have historically renewed these contracts,
although there can be no assurance that customers will do so in the
future.
Adjusted Selling, General and
Administrative (SG&A) Expense and Adjusted SG&A Percentage
We use the term "adjusted SG&A expense” to refer to GAAP SG&A expense,
excluding amortization of intangible assets, and contingent
consideration and other costs related to business acquisitions. We use
the related term "adjusted SG&A percentage” to refer to adjusted SG&A
expense as a percentage of GAAP revenue. We believe that these non-GAAP
measures, when taken together with our GAAP financial measures, allow us
and our investors to better measure the cost of the internal operating
structure, our ability to leverage that structure and the level of
investment required to grow our business. We exclude amortization of
intangible assets and contingent consideration and other costs related
to business acquisitions from these measures because intangibles
amortization charges and contingent consideration and other costs
related to business acquisitions do not represent what our management
and what we believe our investors consider to be costs that support our
internal operating structure and could distort the efficiencies of that
structure.
Adjusted Research and Development
(R&D) Expense and Adjusted R&D Percentage
We use the term "adjusted R&D expense” to refer to GAAP R&D expense,
excluding amortization of intangible assets. We use the related term
"adjusted R&D percentage” to refer to adjusted R&D expense as a
percentage of GAAP revenue. We believe that these non-GAAP measures,
when taken together with our GAAP financial measures, allow us and our
investors to better understand and evaluate our internal technology
investments. We exclude amortization of intangible assets from these
measures because intangibles amortization charges do not represent what
our management and what we believe our investors consider to be internal
investments in R&D activities and could distort our R&D investment level.
Adjusted Operating Profit and Adjusted
Operating Profit Margin
We use the term "adjusted operating profit” to refer to GAAP operating
profit, excluding amortization of intangible assets, inventory fair
value adjustments related to business acquisitions, contingent
consideration and other costs related to business acquisitions, and
restructuring charges, and including estimated revenue from contracts
acquired in the ViaCell acquisition that will not be fully recognized
due to business combination accounting rules. Adjusted operating profit
is calculated by subtracting adjusted R&D expense, adjusted SG&A
expense, and restructuring charges from adjusted gross margin. We use
the related term "adjusted operating profit margin” to refer to adjusted
operating profit as a percentage of GAAP revenue. We believe that these
non-GAAP measures, when taken together with our GAAP financial measures,
allow us and our investors to analyze the costs of the different
components of producing and selling our products, to better measure the
performance of our internal investments in technology and to evaluate
the long-term profitability trends of our core operations. Adjusted
operating profit also provides for easier comparisons of our performance
and profitability with prior and future periods and relative comparisons
to our peers. We believe our investors do not consider the items that we
exclude from adjusted operating profit to be costs of producing our
products, investments in technology and production, and costs to support
our internal operating structure, and so we present this non-GAAP
measure to avoid overstating or understating to our investors the
performance of our operations. We exclude restructuring charges because
they tend to occur due to an acquisition, divestiture, repositioning of
the business or other unusual event that could distort the performance
measures of our internal investments and costs to support our internal
operating structure. We include estimated revenue from contracts
acquired in the ViaCell acquisition that will not be fully recognized
because our GAAP revenue for the periods subsequent to our acquisition
do not reflect the full amount of storage revenue on these contracts
that would have otherwise been recorded by ViaCell. The non-GAAP
adjustment is intended to reflect the full amount of such revenue. Our
management and we believe our investors will use this adjustment as a
measure of the ongoing performance of the ViaCell business because
customers have historically renewed these contracts, although there can
be no assurance that customers will do so in the future.
Adjusted Earnings per Share
We use the term "adjusted earnings per share,” or "adjusted EPS,” to
refer to GAAP earnings per share, excluding discontinued operations,
amortization of intangible assets, inventory fair value adjustments
related to business acquisitions, contingent consideration and other
costs related to business acquisitions, and restructuring charges, and
including estimated revenue from contracts acquired in the ViaCell
acquisition that will not be fully recognized due to business
combination accounting rules. Adjusted earnings per share is calculated
by subtracting adjusted R&D expense, adjusted SG&A expense,
restructuring charges, other income/expense and provision for taxes from
adjusted gross margin. We believe that this non-GAAP measure, when taken
together with our GAAP financial measures, allows us and our investors
to analyze the costs of producing and selling our products and the
performance of our internal investments in technology and our internal
operating structure, to evaluate the long-term profitability trends of
our core operations and to calculate the underlying value of the core
business on a dilutive share basis, which is a key measure of the value
of the Company used by our management and we believe used by investors
as well. Adjusted earnings per share also facilitates the overall
analysis of the value of the Company and the core measure of the success
of our operating business model as compared to prior and future periods
and relative comparisons to our peers. We exclude discontinued
operations, amortization of intangible assets, inventory fair value
adjustments related to business acquisitions, contingent consideration
and other costs related to business acquisitions, and restructuring
charges as these items do not represent what our management and what we
believe our investors consider to be costs of producing our products,
investments in technology and production, and costs to support our
internal operating structure, which could result in overstating or
understating to our investors the performance of our operations. We
include estimated revenue from contracts acquired in the ViaCell
acquisition that will not be fully recognized because our GAAP revenue
for the periods subsequent to our acquisition do not reflect the full
amount of storage revenue on these contracts that would have otherwise
been recorded by ViaCell. The non-GAAP adjustment is intended to reflect
the full amount of such revenue. Our management and we believe our
investors will use this adjustment as a measure of the ongoing
performance of the ViaCell business because customers have historically
renewed these contracts, although there can be no assurance that
customers will do so in the future.
Adjusted Operating Cash Flow
We use the term "adjusted operating cash flow” to refer to GAAP
operating cash flow from continuing operations, excluding the effect of
changes in our accounts receivable securitization facility. We believe
that this non-GAAP measure, when taken together with our GAAP financial
measure, allows us and our investors to better evaluate the long-term
performance trends and to assess our ability to invest in the business.
Adjusted operating cash flow also provides for easier comparisons of our
performance with prior and future periods and relative comparisons to
our peers. We exclude the effect of changes in our accounts receivable
securitization facility from this measure because changes in our
accounts receivable securitization facility can vary dramatically by
quarter and between us and our peers and can obscure underlying trends,
which we believe makes comparisons of long-term performance trends
difficult for management and investors, and could result in overstating
or understating to our investors the performance of our operations.
* * * *
The non-GAAP financial measures described above are not meant to be
considered superior to, or a substitute for, our financial statements
prepared in accordance with GAAP. There are material limitations
associated with non-GAAP financial measures because they exclude charges
that have an effect on our reported results and, therefore, should not
be relied upon as the sole financial measures to evaluate our financial
results. Management compensates and believes that investors should
compensate for these limitations by viewing the non-GAAP financial
measures in conjunction with the GAAP financial measures. In addition,
the non-GAAP financial measures included in this earnings announcement
may be different from, and therefore may not be comparable to, similar
measures used by other companies.
Each of the non-GAAP financial measures listed above are also used by
our management to evaluate our operating performance, communicate our
financial results to our Board of Directors, benchmark our results
against our historical performance and the performance of our peers,
evaluate investment opportunities including acquisitions and
discontinued operations, and determine the bonus payments for senior
management and employees.
